The Therapeutic Utility of mRNA for The Expression of Therapeutic Proteins
RNA Therapeutics 2016, 15th & 16th February, Holiday Inn Kensington Forum, London UK
London, United Kingdom, January 06, 2016 --(PR.com)-- SMi are delighted to have Heinrich Haas, Vice President of RNA Formulation and Drug Development at BioNTech AG, present at the 7th annual conference on RNA Therapeutics when it returns to London next month.
With over 20 years of experience in academic research and pharmaceutical development, Dr Heinrich Haas helped build the formulation development and analytics unit which develops formulations for delivery of RNA and small molecules at BioNTech.
Dr Haas has an active record of publications in peer-reviewed journals and patent applications in the field of drug delivery. His current professional focus is on liposome / nanoparticle products and formulations for targeted drug delivery.
With a focus on chemical modifications of mRNA, his presentation entitled: The Therapeutic Utility of mRNA for the expression of Therapeutic Proteins, will discuss how to optimise expression of the specific therapeutic protein; robust delivery and release to minimize dosage frequency, immunogenicity and toxicity; and assesses intracellular function and human translatable results.
Exploring game-changing developments of RNA-based nanotechnologies, the new agenda for RNA Therapeutics 2016 will provide progressive insights from many other industry leading biopharmaceutical companies such as: Sarepta Therapeutics, Rigontech, Isis Pharmaceuticals, Curevac, MiNA Therapeutics, Sylentis, GlobalAcorn, plus many more.
A full speaker line-up and detailed conference agenda is available to download online at www.therapeutics-rna.com/prcom
RNA Therapeutics
15th and 16th February 2016
Holiday Inn Kensington Forum, London UK
About SMi:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world�s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
About BioNTech AG:
BioNTech AG (Biopharmaceutical New Technologies, Mainz, Germany) develops innovative therapeutics and biomarker-based diagnostics. The company, founded in 2008, is the result of years of pioneering research and groundbreaking achievements. BioNTech’s initial three digit million first-round financing was among the largest initial financing rounds in the history of the biopharmaceutical sector. BioNTech AG is a holding company; together with its subsidiaries, the company offers a spectrum of competencies, innovations and products under one strategic umbrella. More information can be found at http://biontech.de/
With over 20 years of experience in academic research and pharmaceutical development, Dr Heinrich Haas helped build the formulation development and analytics unit which develops formulations for delivery of RNA and small molecules at BioNTech.
Dr Haas has an active record of publications in peer-reviewed journals and patent applications in the field of drug delivery. His current professional focus is on liposome / nanoparticle products and formulations for targeted drug delivery.
With a focus on chemical modifications of mRNA, his presentation entitled: The Therapeutic Utility of mRNA for the expression of Therapeutic Proteins, will discuss how to optimise expression of the specific therapeutic protein; robust delivery and release to minimize dosage frequency, immunogenicity and toxicity; and assesses intracellular function and human translatable results.
Exploring game-changing developments of RNA-based nanotechnologies, the new agenda for RNA Therapeutics 2016 will provide progressive insights from many other industry leading biopharmaceutical companies such as: Sarepta Therapeutics, Rigontech, Isis Pharmaceuticals, Curevac, MiNA Therapeutics, Sylentis, GlobalAcorn, plus many more.
A full speaker line-up and detailed conference agenda is available to download online at www.therapeutics-rna.com/prcom
RNA Therapeutics
15th and 16th February 2016
Holiday Inn Kensington Forum, London UK
About SMi:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world�s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
About BioNTech AG:
BioNTech AG (Biopharmaceutical New Technologies, Mainz, Germany) develops innovative therapeutics and biomarker-based diagnostics. The company, founded in 2008, is the result of years of pioneering research and groundbreaking achievements. BioNTech’s initial three digit million first-round financing was among the largest initial financing rounds in the history of the biopharmaceutical sector. BioNTech AG is a holding company; together with its subsidiaries, the company offers a spectrum of competencies, innovations and products under one strategic umbrella. More information can be found at http://biontech.de/
Contact
SMi Group
Teri Arri
+44 (0)20 7827 6162
http://www.therapeutics-rna.com/prcom
Teri Arri
+44 (0)20 7827 6162
http://www.therapeutics-rna.com/prcom
Contact
Categories